This post is informational only. It is not medical advice. Dosing decisions for Semaglutide should be made with your prescribing provider, who knows your full clinical picture. Verify every dose against your vial label and the prescribing information.
If you're starting Semaglutide — under any of the brand names: Ozempic®, Wegovy®, or the oral form Rybelsus® — you'll usually start at a dose far below the maintenance target and step up over several months. That ramp is called titration, and it's not arbitrary: it's specifically designed to let your gastrointestinal system adapt to the drug's effect on gastric emptying.
This guide walks through the standard 16-week titration ramp from the FDA-approved label, why each step exists, and the side-effect pattern most people see along the way.
Why titration exists
Semaglutide is a GLP-1 receptor agonist. The same mechanism that produces appetite suppression and improved glycemic regulation — slowed gastric emptying — is also the dominant source of side effects, especially nausea, fatigue, and constipation in the first weeks at any new dose.
Going straight to a maintenance dose without titration is correlated with significantly worse tolerability. Stepping up gives the gut time to adjust at each level before the next increase.
Titration is not optional. The FDA-approved label specifies it for both Ozempic and Wegovy, and providers titrate even when patients ask for a faster ramp.
The standard 16-week ramp
This is the schedule listed in the Semaglutide prescribing information for once-weekly subcutaneous injection:
| Phase | Weeks | Dose |
|---|---|---|
| Ramp 1 | 1–4 | 0.25 mg / week |
| Ramp 2 | 5–8 | 0.50 mg / week |
| Ramp 3 | 9–12 | 1.0 mg / week |
| Ramp 4 | 13–16 | 1.7 mg / week |
| Maintenance | 17+ | 2.4 mg / week (Wegovy max) |
A few things worth noting:
- 0.25 mg is not a therapeutic dose. It's a starter dose specifically to let your body adapt — the appetite-suppression effect at 0.25 mg is minimal for most users. The benefit of starting here is purely about avoiding side-effect overwhelm.
- The 1.7 mg step in week 13 was added in later revisions of the label to give a smoother on-ramp to the 2.4 mg maintenance dose.
- 2.4 mg is the maximum approved dose for Wegovy (chronic weight management). For Ozempic (type-2 diabetes) the typical maintenance dose is 1.0 mg with an option to escalate to 2.0 mg.
If you want to see what the math looks like for your specific vial, the free reconstitution calculator on this site preselects the Semaglutide schedule:
Inputs
Semaglutide common vial sizes: 3 mg, 5 mg, 10 mg. Typical dose range: 0.25–2.4 mg. Public clinical dosing guidance. Not medical advice.
for a 0.25 mg dose
- Concentration
- 3.00 mg/ml
- Volume
- 0.083 ml
- Per ml
- 100 u
Not medical advice. Always verify against your vial label and your provider's instructions. Re-check before drawing.
What to expect at each step
The side-effect timeline most users describe follows a predictable pattern. The first 5–7 days after a dose increase are the worst; the next 2–3 weeks at the new dose are generally smoother.
| Phase | Common in the first week | What usually settles |
|---|---|---|
| Ramp 1 (0.25 mg) | Mild nausea, fatigue, occasional headache | Most resolve by day 5–7 |
| Ramp 2 (0.5 mg) | Nausea returns briefly, constipation may begin | Usually settles by day 10 |
| Ramp 3 (1.0 mg) | Nausea, GI changes, some users report sulfur burps | Typically tolerable by week 2 |
| Ramp 4 (1.7 mg) | Significant appetite suppression, possible fatigue | Adapts over 2–3 weeks |
| Maintenance (2.4 mg) | Usually the smoothest phase; side effects from earlier ramps fade | Steady state |
The label also lists more serious adverse events — pancreatitis, gallbladder disease, severe dehydration. These are rare but real. Stop the medication and contact your provider for severe abdominal pain, persistent vomiting, or signs of dehydration.
When to hold a step
Most providers will pause the ramp and stay at the current dose for an additional 2–4 weeks if any of the following apply:
- Nausea or vomiting that interferes with adequate hydration or nutrition
- New-onset abdominal pain that doesn't resolve
- Persistent fatigue significant enough to disrupt work or daily activities
- Rapid weight loss exceeding the expected pace, with signs of muscle loss
There's no penalty for taking 20 weeks instead of 16 to reach maintenance. The label-approved schedule is the minimum tolerable pace for most users — not a target.
If you're considering changing your dose or schedule, talk to your prescribing provider before doing anything. Adjusting Semaglutide without supervision — including stopping abruptly — can produce both short-term GI rebound and longer-term metabolic regression.
How the iOS app supports a titration cycle
If you're running this protocol, the iOS app will:
- Auto-advance the dose week by week so you never have to remember which step you're on
- Calculate the exact units for each step's dose against your vial size
- Track injection sites on a body map so you don't reuse the same spot
- Log side effects on a timeline, so you can show your provider whether symptoms are settling or worsening
- Export a doctor-ready PDF with your full ramp history, dose log, weight trend, and side-effect pattern
Track Semaglutide in the app: open the App Store listing.
References
The dose schedule and adverse-event data above are taken directly from the FDA-approved prescribing information for Semaglutide. For the authoritative source — and for any changes the FDA has issued since this post — see:
For more on how this site curates its data and which databases it cross-checks against, see the resources page.